Who and how to screen for cancer in at-risk inflammatory bowel disease patients

References

• Greenstein AJ, Sachar DB, Smith H, et al. Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology 1979;77:290-4
   PubMed Web of Science ®Google Scholar
• Eaden J, Abrams K, Mayberry J. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35
   PubMed Web of Science ®Google Scholar
• Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130(4):1030-8
   PubMed Web of Science ®Google Scholar
• Loftus EV. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am 2006;35(3):517-31
   PubMed Web of Science ®Google Scholar
• Jess T, Loftus EV, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology 2006;130(4):1039-46
   PubMed Web of Science ®Google Scholar
• Hendriksen C, Kreiner S. Long term prognosis in ulcerative colitis—based on results from a regional patient group from the county of Copenhagen. Gut 1985;26:158-63
   PubMed Web of Science ®Google Scholar
• Söderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009;136(5):1561-7
   PubMed Web of Science ®Google Scholar
• Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007;13(4):481-9
   PubMed Web of Science ®Google Scholar
• Wandall EP, Damkier P, Møller Pedersen F, et al. Survival and incidence of colorectal cancer in patients with ulcerative colitis in Funen County diagnosed between 1973 and 1993. Scand J Gastroenterol 2000;35(3):312-17
   PubMed Web of Science ®Google Scholar
• Palli D, Trallori G, Bagnoli S, et al. Hodgkin’s disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000;119(3):647-53
   PubMed Web of Science ®Google Scholar
• Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2(12):1088-95
   PubMed Web of Science ®Google Scholar
• Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10(6):639-45
   PubMed Web of Science ®Google Scholar
• Stewénius J, Adnerhill I, Anderson H, et al. Incidence of colorectal cancer and all cause mortality in non-selected patients with ulcerative colitis and indeterminate colitis in Malmö, Sweden. Int J Colorectal Dis 1995;10(2):117-22
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91(4):854-62
   PubMed Web of Science ®Google Scholar
• Jussila A, Virta LJ, Pukkala E, et al. Malignancies in patients with inflammatory bowel disease: a nationwide register study in finland. Scand J Gastroenterol 2013;48(12):1405-13
   PubMed Web of Science ®Google Scholar
• Manninen P, Karvonen AL, Huhtala H, et al. The risk of colorectal cancer in patients with inflammatory bowel diseases in Finland: a follow-up of 20 years. J Crohns Colitis 2013;7(11):e551-7
   PubMedGoogle Scholar
• Jess T, Horváth-Puhó E, Fallingborg J, et al. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol 2013;108:1869-76
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol 2014;12(2):265-73
   PubMed Web of Science ®Google Scholar
• Weedon AA, Shorter RG, Ilstrup DM, et al. Crohn’s Disease and cancer. N Engl J Med 1973;289(21):1099-103
   PubMed Web of Science ®Google Scholar
• Gyde SN, Prior P, Macartney JC, et al. Malignancy in Crohn’s disease. Gut 1980;21(12):1024-9
   PubMed Web of Science ®Google Scholar
• Greenstein AJ, Sachar DB, Smith H, et al. A comparison of cancer risk in Crohn’s disease and ulcerative colitis. Cancer 1981;48(12):2742-5
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 1990;336:357-9
   PubMed Web of Science ®Google Scholar
• Gillen CD, Walmsley RS, Prior P, et al. Crohn’s disease and colorectal cancer. Gut 1994;35(5):651-5
   PubMed Web of Science ®Google Scholar
• Gollop JH, Phillips SF, Melton LJ3rd, et al. Epidemiologic aspects of Crohn’s disease: a population based study in Olmsted County, Minnesota, 1943-1982. Gut 1988;29(1):49-56
   PubMed Web of Science ®Google Scholar
• Fireman Z, Grossman A, Lilos P, et al. Intestinal cancer in patients with Crohn’s disease. a population study in central Israel. Scand J Gastroenterol 1989;24(3):346-50
   PubMed Web of Science ®Google Scholar
• Persson PG, Karlén P, Bernell O, et al. Crohn’s disease and cancer: a population-based cohort study. Gastroenterology 1994;107(6):1675-9
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Johansen C, Gridley G, et al. Crohn’s disease and cancer risk (Denmark). Cancer Causes Control 2000;11(2):145-50
   PubMed Web of Science ®Google Scholar
• Canavan C, Abrams KR, Mayberry J. Meta analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther 2006;23(8):1097-104
   PubMed Web of Science ®Google Scholar
• Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013;19(4):789-99
   PubMed Web of Science ®Google Scholar
• Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100(12):2724-9
   PubMed Web of Science ®Google Scholar
• Gillen CD, Walmsley RS, Prior P, et al. Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 1994;35:1590-2
   PubMed Web of Science ®Google Scholar
• Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994;35:950-4
   PubMed Web of Science ®Google Scholar
• Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004;19(3):287-93
   PubMed Web of Science ®Google Scholar
• Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010;138:738-45
   PubMed Web of Science ®Google Scholar
• Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59(5):666-89
   PubMed Web of Science ®Google Scholar
• Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013;7(12):982-1018
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Cagan A, Cai T, et al. Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• van den Broek FJ, Stokkers PC, Reitsma JB, et al. Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences. Am J Gastroenterol 2014;109(5):715-22
   PubMed Web of Science ®Google Scholar
• Buchner AM, Shahid MW, Heckman MG, et al. High-definition colonoscopy detects colorectal polyps at a higher rate than standard white-light colonoscopy. Clin Gastroenterol Hepatol 2010;8(4):364-70
   PubMed Web of Science ®Google Scholar
• Kiesslich R, Neurath MF. Chromoendoscopy: an evolving standard in surveillance for ulcerative colitis. Inflamm Bowel Dis 2004;10(5):695-6
   PubMed Web of Science ®Google Scholar
• Subramanian V, Mannath J, Ragunath K, et al. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther 2011;33(3):304-12
   PubMed Web of Science ®Google Scholar
• Kahi CJ, Anderson JC, Waxman I, et al. High-definition chromocolonoscopy vs. high-definition white light colonoscopy for average-risk colorectal cancer screening. Am J Gastroenterol 2010;105(6):1301-7
   PubMed Web of Science ®Google Scholar
• Dekker E, van den Broek FJ, Reitsma JB, et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy 2007;39(3):216-21
   PubMed Web of Science ®Google Scholar
• van den Broek FJ, Fockens P, van Eeden S, et al. Narrow-band imaging versus high-definition endoscopy for the diagnosis of neoplasia in ulcerative colitis. Endoscopy 2011;43(2):108-15
   PubMed Web of Science ®Google Scholar
• Ignjatovic A, East JE, Subramanian V, et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Am J Gastroenterol 2012;107(6):885-90
   PubMed Web of Science ®Google Scholar
• Aminalai A, Rösch T, Aschenbeck J, et al. Live image processing does not increase adenoma detection rate during colonoscopy: a randomized comparison between FICE and conventional imaging (Berlin Colonoscopy Project 5, BECOP-5). Am J Gastroenterol 2010;105(11):2383-8
   PubMed Web of Science ®Google Scholar
• Hoffman A, Sar F, Goetz M, et al. High definition colonoscopy combined with i-Scan is superior in the detection of colorectal neoplasias compared with standard video colonoscopy: a prospective randomized controlled trial. Endoscopy 2010;42(10):827-33
   PubMed Web of Science ®Google Scholar
• Cha JM, Lee JI, Joo KR, et al. A prospective randomized study on computed virtual chromoendoscopy versus conventional colonoscopy for the detection of small colorectal adenomas. Dig Dis Sci 2010;55(8):2357-64
   PubMed Web of Science ®Google Scholar
• Seaman DL, Gostout CJ, Smyrk TC, et al. Blinded comparison of white light surveillance colonoscopy to endoscopic autofluorescence imaging (AFI) and narrow band imaging (NBI) for detection of dysplasia in patients with chronic ulcerative colitis ± concurrent primary sclerosing cholangitis (PSC). Gastrointest Endosc 2007;65(5):AB349
   Web of Science ®Google Scholar
• Matsumoto T, Nakamura S, Moriyama T, et al. Autofluorescence imaging colonoscopy for the detection of dysplastic lesions in ulcerative colitis: a pilot study. Colorectal Dis 2010;12(10 Online):e291-7
   PubMed Web of Science ®Google Scholar
• van den Broek FJ, Fockens P, van Eeden S, et al. Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. Gut 2008;57(8):1083-9
   PubMed Web of Science ®Google Scholar
• Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 2007;132(3):874-82
   PubMed Web of Science ®Google Scholar
• van den Broek FJ, van Es JA, van Eeden S, et al. Pilot study of probe-based confocal laser endomicroscopy during colonoscopic surveillance of patients with longstanding ulcerative colitis. Endoscopy 2011;43(2):116-22
   PubMed Web of Science ®Google Scholar
• Rispo A, Castiglione F, Staibano S, et al. Diagnostic accuracy of confocal laser endomicroscopy in diagnosing dysplasia in patients affected by long-standing ulcerative colitis. World J Gastrointest Endosc 2012;4(9):414-20
   PubMedGoogle Scholar
• Marion JF, Waye JD, Present DH, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol 2008;103(9):2342-9
   PubMed Web of Science ®Google Scholar
• Hlavaty T, Huorka M, Koller T, et al. Colorectal cancer screening in patients with ulcerative and Crohn’s colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. Eur J Gastroenterol Hepatol 2011;23(8):680-9
   PubMed Web of Science ®Google Scholar
• Günther U, Kusch D, Heller F, et al. Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random biopsy vs. targeted biopsy protocols. Int J Colorectal Dis 2011;26(5):667-72
   PubMed Web of Science ®Google Scholar
• Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004;53:1813-16
   PubMed Web of Science ®Google Scholar
• Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133(4):1099-105
   PubMed Web of Science ®Google Scholar
• Mathy C, Schneider K, Chen YY, et al. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis 2003;9(6):351-5
   PubMed Web of Science ®Google Scholar
• Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 2013;11(12):1601-8
   PubMed Web of Science ®Google Scholar
• Nieminen U, Jussila A, Nordling S, et al. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. Int Cancer J 2014;134(1):189-96
   PubMed Web of Science ®Google Scholar
• Fausa O, Schrumpf E, Elgjo K. Relationship of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Semin Liver Dis 1991;11:31-9
   PubMed Web of Science ®Google Scholar
• Rasmussen HH, Fallingborg JF, Mortensen PB, et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn’s disease. Scand J Gastroenterol 1997;32(6):604-10
   PubMed Web of Science ®Google Scholar
• Olsson R, Danielsson A, Järnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319-23
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011;53:1590-9
   PubMed Web of Science ®Google Scholar
• Broomé U, Olsson R, Lööf L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-15
   PubMed Web of Science ®Google Scholar
• Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980;21:870-7
   PubMed Web of Science ®Google Scholar
• Broomé U, Löfberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995;22(5):1404-8
   PubMed Web of Science ®Google Scholar
• Aitola P, Mattila J, Matikainen M. Liver involvement in patients operated for ulcerative colitis, with special reference to the association of cholangitis with colorectal dysplasia and carcinoma. Int J Colorectal Dis 2000;15(3):167-71
   PubMed Web of Science ®Google Scholar
• Brentnall TA, Haggitt RC, Rabinovitch PS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996;110(2):331-8
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 1993;88(8):1174-8
   PubMed Web of Science ®Google Scholar
• Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997;41(4):522-5
   PubMed Web of Science ®Google Scholar
• Marchesa P, Lashner BA, Lavery IC, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997;92(8):1285-8
   PubMed Web of Science ®Google Scholar
• Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999;94(6):1643-9
   PubMed Web of Science ®Google Scholar
• Moayyeri A, Daryani NE, Bahrami H, et al. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J Gastroenterol Hepatol 2005;20(3):366-70
   PubMed Web of Science ®Google Scholar
• Lundqvist K, Broomé U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997;40:451-6
   PubMed Web of Science ®Google Scholar
• Loftus EVJr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91-6
   PubMed Web of Science ®Google Scholar
• Sokol H, Cosnes J, Chazouilleres O, et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 2008;14:3497-503
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Heitman SJ, Hilsden RJ, et al. Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis. Inflamm Bowel Dis 2007;13:1401-7
   PubMed Web of Science ®Google Scholar
• Broomé U, Lindberg G, Löfberg R. Primary sclerosing cholangitis in ulcerative colitis--a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992;102:1877-80
   PubMed Web of Science ®Google Scholar
• Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56:48-54
   PubMed Web of Science ®Google Scholar
• Rudolph G, Gotthardt D, Kloeters Plachky P, et al. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol 2010;53:313-17
   PubMed Web of Science ®Google Scholar
• Balan V, LaRusso NF. Hepatobiliary disease in inflammatory bowel disease. Gastroenterol Clin North Am 1995;24(3):647-69
   PubMed Web of Science ®Google Scholar
• Rudolph G, Endele R, Senn M, et al. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis. Hepatology 1993;17(6):1028-32
   PubMed Web of Science ®Google Scholar
• Jazrawi RP, de Caestecker JS, Goggin PM, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994;106(1):134-42
   PubMed Web of Science ®Google Scholar
• Lindberg BU, Broomé U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001;44:77-85
   PubMed Web of Science ®Google Scholar
• Claessen MM, Lutgens MW, van Buuren HR, et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009;15:1331-6
   PubMed Web of Science ®Google Scholar
• Thackeray EW, Charatcharoenwitthaya P, Elfaki D, et al. Colon Neoplasms Develop Early in the Course of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol 2011;9:52-6
   PubMed Web of Science ®Google Scholar
• Nagengast FM, Grubben MJ, van Munster IP. Role of bile acids in colorectal carcinogenesis. Eur Cancer J 1995;31A(7–8):1067-70
   PubMed Web of Science ®Google Scholar
• Hill MJ, Melville DM, Lennard-Jones JE, et al. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet 1987;2(8552):185-6
   PubMed Web of Science ®Google Scholar
• Summerton J, Flynn M, Cooke T, et al. Bile acid receptors in colorectal cancer. Br J Surg 1983;70(9):549-51
   PubMed Web of Science ®Google Scholar
• Hanouneh IA, MacAron C, Lopez R, et al. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis 2012;18:269-74
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Lindström L, Cvancarova M, et al. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastroenterol 2012;47:1021-9
   PubMed Web of Science ®Google Scholar
• European association for the study of the liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009;51(2):237-67
   PubMed Web of Science ®Google Scholar
• Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51(2):660-78
   PubMed Web of Science ®Google Scholar
• Wilschut JA, Habbema JD, Ramsey SD, et al. Increased risk of adenomas in individuals with a family history of colorectal cancer: results of a meta-analysis. Cancer Causes Control 2010;21:2287-93
   PubMed Web of Science ®Google Scholar
• Nuako KW, Ahlquist DA, Mahoney DW, et al. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 1998;115:1079-83
   PubMed Web of Science ®Google Scholar
• Askling J, Dickman PW, Karlén P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001;120:1356-62
   PubMed Web of Science ®Google Scholar
• Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010;138(2):746-74
   PubMed Web of Science ®Google Scholar
• Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988;29:206-17
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33
   PubMed Web of Science ®Google Scholar
• Devroede GJ, Taylor WF, Sauer WG, et al. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med 1971;285:17-21
   PubMed Web of Science ®Google Scholar
• Markowitz J, McKinley M, Kahn E, et al. Endoscopic screening for dysplasia and mucosal aneuploidy in adolescents and young adults with childhood onset colitis. Am J Gastroenterol 1997;92:2001-6
   PubMed Web of Science ®Google Scholar
• Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut 1992;33(7):938-41
   PubMed Web of Science ®Google Scholar
• Ky A, Sohn N, Weinstein MA, et al. Carcinoma arising in anorectal fistulas of Crohn’s disease. Dis Colon Rectum 1998;41(8):992-6
   PubMed Web of Science ®Google Scholar
• Connell WR, Sheffield JP, Kamm MA, et al. Lower gastrointestinal malignancy in Crohn’s disease. 1994;35:347-52
   Google Scholar
• Winslett MC, Allan A, Ambrose NS. Anorectal sepsis as a presentation of occult rectal and systemic disease. Dis Colon Rectum 1988;31(8):597-600
   PubMed Web of Science ®Google Scholar
• Nelson RL, Prasad ML, Abcarian H. Anal carcinoma presenting as a perirectal abscess or fistula. Arch Surg 1985;120(5):632-5
   PubMedGoogle Scholar
• Iesalnieks I, Gaertner WB, Glass H, et al. Fistula-associated anal adenocarcinoma in Crohn’s disease. Inflamm Bowel Dis 2010;16(10):1643-8
   PubMed Web of Science ®Google Scholar
• Egan L, D’Inca R, Jess T, et al. Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (II). J Crohns Colitis 2014;8(1):19-30
   PubMed Web of Science ®Google Scholar
• Velayos FS, Loftus EV, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006;130(7):1941-9
   PubMed Web of Science ®Google Scholar
• Derikx LA, Kievit W, Drenth JP, et al. Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease. Gastroenterology 2014;146(1):119-28
   PubMed Web of Science ®Google Scholar
• Kariv R, Remzi FH, Lian L, et al. Preoperative colorectal neoplasia increases risk for pouch neoplasia in patients with restorative proctocolectomy. Gastroenterology 2010;139(3):806-12
   PubMed Web of Science ®Google Scholar
• Remzi FH, Fazio VW, Delaney CP, et al. Dysplasia of the anal transitional zone after ileal pouch-anal anastomosis: results of prospective evaluation after a minimum of ten years. Dis Colon Rectum 2003;46(1):6-13
   PubMed Web of Science ®Google Scholar
• Ziv Y, Fazio VW, Sirimarco MT, et al. Incidence, risk factors, and treatment of dysplasia in the anal transitional zone after ileal pouch-anal anastomosis. Dis Colon Rectum 1994;37(12):1281-5
   PubMed Web of Science ®Google Scholar
• Sagayama K, Ikeuchi H, Nishigami T, et al. Incidence of and risk factors for dysplasia in mucosectomy area in ulcerative colitis patients undergoing restorative proctocolectomy. Int J Colorectal Dis 2007;22(4):439-43
   PubMed Web of Science ®Google Scholar
• Veress B, Reinholt FP, Lindquist K, et al. Long-term histomorphological surveillance of the pelvic ileal pouch: dysplasia develops in a subgroup of patients. Gastroenterology 1995;109(4):1090-7
   PubMed Web of Science ®Google Scholar
• Gullberg K, Ståhlberg D, Liljeqvist L, et al. Neoplastic transformation of the pelvic pouch mucosa in patients with ulcerative colitis. Gastroenterology 1997;112(5):1487-92
   PubMed Web of Science ®Google Scholar
• Banasiewicz T, Marciniak R, Paszkowski J, et al. Pouchitis may increase the risk of dysplasia after restorative proctocolectomy in patients with ulcerative colitis. Colorectal Dis 2012;14(1):92-7
   PubMed Web of Science ®Google Scholar
• Ståhlberg D, Veress B, Tribukait B, et al. Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum 2003;46(6):770-8
   PubMed Web of Science ®Google Scholar
• Rahman M, Desmond P, Mortensen N, et al. The clinical impact of primary sclerosing cholangitis in patients with an ileal pouch-anal anastomosis for ulcerative colitis. Int J Colorectal Dis 2011;26(5):553-9
   PubMed Web of Science ®Google Scholar
• Hemminki K, Li X, Sundquist J, et al. Cancer risks in Crohn disease patients. Ann Oncol 2009;20(3):574-80
   PubMed Web of Science ®Google Scholar
• von Roon AC, Reese G, Teare J, et al. The risk of cancer in patients with Crohn’s disease. Dis Colon Rectum 2007;50(6):839-55
   PubMed Web of Science ®Google Scholar
• Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-7
   PubMed Web of Science ®Google Scholar
• Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002;37:1205-11
   PubMed Web of Science ®Google Scholar
• Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000;31:7-11
   PubMed Web of Science ®Google Scholar
• Ahrendt SA, Pitt HA, Nakeeb A, et al. Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Surg 1999;3:357-67
   PubMed Web of Science ®Google Scholar
• Lichtenstein DR. Hepatobiliary complications of inflammatory bowel disease. Curr Gastroenterol Rep 2011;13:495-505
   PubMedGoogle Scholar
• Fevery J, Verslype C, Lai G, et al. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007;52:3123-35
   PubMed Web of Science ®Google Scholar
• Razumilava N, Gores G, Lindor K. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011;54:1842-52
   PubMed Web of Science ®Google Scholar
• Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687-701
   PubMed Web of Science ®Google Scholar
• Madan V, Lear JT, Szeimies MR. Non-melanoma skin cancer. Lancet 2010;375:673-85
   PubMed Web of Science ®Google Scholar
• Jensen P, Hansen S, Møller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999;40(2 Pt 1):177-86
   PubMed Web of Science ®Google Scholar
• Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91
   PubMed Web of Science ®Google Scholar
• Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010;8:268-74
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-8
   PubMed Web of Science ®Google Scholar
• Singh H, Nugent Z, Demers AA, et al. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011;141:1612-20
   PubMed Web of Science ®Google Scholar
• Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143:390-9
   PubMed Web of Science ®Google Scholar
• Setshedi M, Epstein D, Winter TA, et al. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012;27:385-9
   PubMed Web of Science ®Google Scholar
• Subramaniam K, Pavli P. Risk of non-melanoma skin cancer with thiopurine use in inflammatory bowel disease. J Gastroenterol Hepatol 2012;27(2):193-4
   PubMed Web of Science ®Google Scholar
• Parrish JA. Immunosuppression, skin cancer, and ultraviolet A radiation. N Engl J Med 2005;353:2712-13
   PubMed Web of Science ®Google Scholar
• Okafor PN, Stallwood CG, Nguyen L, et al. Cost-effectiveness of nonmelanoma skin cancer screening in Crohn’s disease patients. Inflamm Bowel Dis 2013;19:2787-95
   PubMed Web of Science ®Google Scholar
• Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (III). J Crohns Colitis 2014;8(1):31-44
   PubMed Web of Science ®Google Scholar
• Psaty EL, Scope A, Halpern AC, et al. Defining the patient at high risk for melanoma. Int J Dermatol 2010;49:362-76
   PubMed Web of Science ®Google Scholar
• Simard EP, Ward EM, Siegel R, et al. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62:118-28
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong JS, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67:2015-19
   PubMed Web of Science ®Google Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 2013;72(4):517-24
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Chevaux BJ, Bouvier MA, et al. Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased. Am J Gastroenterol 2012;107(9):1443-4
   PubMed Web of Science ®Google Scholar
• Lund JL, Sturmer T, Porter CQ, et al. Thiazolidinedione use and ulcerative colitis-related flares: an exploratory analysis of administrative data. Inflamm Bowel Dis 2011;17:787-94
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81
   PubMed Web of Science ®Google Scholar
• Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010;105:1480-7
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, et al. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology 1991;100:350-8
   PubMed Web of Science ®Google Scholar
• Katsanos KH, Vermeire S, Christodoulou DK, et al. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion 2007;75:113-21
   PubMed Web of Science ®Google Scholar
• Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12(2):210-18
   PubMed Web of Science ®Google Scholar
• Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101(1):3-27
   PubMed Web of Science ®Google Scholar
• Ekström-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma-a review. Acta Oncol 2006;45(3):258-71
   PubMed Web of Science ®Google Scholar
• Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology 2014;146:941-9
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011;106:2146-53
   PubMed Web of Science ®Google Scholar
• Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-7
   PubMed Web of Science ®Google Scholar
• Kinlen LJ, Sheil AG, Peto J, et al. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979;2(6203):1461-6
   PubMedGoogle Scholar
• Labouyrie E, Morel D, Boiron JM, et al. Peripheral T-cell lymphoma in a chronically immunosuppressed renal transplant patient. Mod Pathol 1995;8(4):355-9
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374(9701):1617-25
   PubMed Web of Science ®Google Scholar
• Loftus EV, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000;95(9):2308-12
   PubMed Web of Science ®Google Scholar
• Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54(8):1121-5
   PubMed Web of Science ®Google Scholar
• Kamel OW, van de Rijn M, Hanasono MM, et al. Immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma 1995;16(5–6):363-8
   PubMed Web of Science ®Google Scholar
• Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99(11):3909-15
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012;107(9):1409-22
   PubMed Web of Science ®Google Scholar
• Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-904
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? Gut 2012;61(4):476-83
   PubMed Web of Science ®Google Scholar
• Dayharsh GA, Loftus EV, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122(1):72-7
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Blonski W, Diamond RH, et al. Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol 2010;105(10):2299-301
   PubMed Web of Science ®Google Scholar
• Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis 2010;4(5):511-22
   PubMed Web of Science ®Google Scholar
• Busnach G, Piselli P, Arbustini E, et al. Immunosuppression and cancer: a comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transplant Proc 2006;38:3533-5
   PubMed Web of Science ®Google Scholar
• Santana IU, do Gomes NA, Lyrio LD, et al. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol 2011;30:665-72
   PubMed Web of Science ®Google Scholar
• Tam LS, Chan PK, Ho SC, et al. Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: a prospective cohort study. Arthritis Care Res (Hoboken) 2011;63:269-76
   PubMed Web of Science ®Google Scholar
• Rojo-Contreras W, Olivas-Flores EM, Gamez-Nava JI, et al. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus 2012;21:365-72
   PubMed Web of Science ®Google Scholar
• Contreras WR, Fuentes HM, Gamez Nava JI, et al. Prevalence and cervical human papilloma virus associated factors in patients with rheumatoid arthritis. Ginecol Obstet Mex 2008;76:9-17
   PubMedGoogle Scholar
• Seshadri L, George SS, Vasudevan B, et al. Cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant recipients. Indian J Cancer 2001;38(2–4):92-5
   PubMedGoogle Scholar
• Malouf MA, Hopkins PM, Singleton L, et al. Sexual health issues after lung transplantation: importance of cervical screening. J Hear Lung Transplant 2004;23:894-7
   PubMed Web of Science ®Google Scholar
• Tam LS, Chan AY, Chan PK, et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004;50:3619-25
   PubMed Web of Science ®Google Scholar
• Wheeler CM. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. Obstet Gynecol Clin North Am 2008;35:519-36
   PubMed Web of Science ®Google Scholar
• Dalstein V, Riethmuller D, Prétet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int Cancer J 2003;106:396-403
   PubMed Web of Science ®Google Scholar
• García-Piñeres AJ, Hildesheim A, Herrero R, et al. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res 2006;66:11070-6
   PubMed Web of Science ®Google Scholar
• Sasagawa T, Takagi H, Makinoda S. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother 2012;18:807-15
   PubMed Web of Science ®Google Scholar
• Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008;103:631-6
   PubMed Web of Science ®Google Scholar
• Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol 2006;12:6167-71
   PubMed Web of Science ®Google Scholar
• Singh H, Demers AA, Nugent Z, et al. Risk of Cervical Abnormalities in Women With Inflammatory Bowel Disease: a Population-Based Nested Case-Control Study. Gastroenterology 2009;136:451-8
   PubMed Web of Science ®Google Scholar
• Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol 2009;104:2524-33
   PubMed Web of Science ®Google Scholar
• Hutfless S, Fireman B, Kane S, et al. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:598-605
   PubMed Web of Science ®Google Scholar
• Kim SC, Glynn RJ, Giovannucci E, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Lees CW, Critchley J, Chee N, et al. Lack of association between cervical dysplasia and IBD: A large case-control study. Inflamm Bowel Dis 2009;15:1621-9
   PubMed Web of Science ®Google Scholar
• Long MD, Porter CQ, Sandler RS, et al. Suboptimal rates of cervical testing among women with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009;7:549-53
   PubMed Web of Science ®Google Scholar
• Singh H, Nugent Z, Demers AA, et al. Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis 2011;17:1741-50
   PubMed Web of Science ®Google Scholar
• Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin Number 131: screening for cervical cancer. Obstet Gynecol 2012;120:1222-38
   PubMedGoogle Scholar
• Villa LL, Perez G, Kjaer SK, et al. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. N Engl J Med 2007;356:1915-27
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-90
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125-32
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-19
   PubMed Web of Science ®Google Scholar
• Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8
   PubMed Web of Science ®Google Scholar
• Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol 2007;13:6134-9
   PubMed Web of Science ®Google Scholar
• Boffetta P. Tobacco smoking and risk of bladder cancer. Scand J Urol Nephrol Suppl 2008;218:45-54
   Google Scholar
• Feuerstein JD, Akbari M, Gifford AE, et al. Systematic review: the quality of the scientific evidence and conflicts of interest in international inflammatory bowel disease practice guidelines. Aliment Pharmacol Ther 2013;37:937-46
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013;7(1):1-33
   PubMed Web of Science ®Google Scholar